# info@crystallizationsummit.com

Category : 2023 Abstracts

Nirmatrelvir crystallization – process evolution from milligram to Metric ton scale through sustainability lens.

By Dr. Samir Kulkarni, Ph.D. Pfizer, Groton, CT The improved development and scaleup of Nirmatrelvir (the active 3CL protease inhibitor in PaxlovidTM) with efficient chemical synthesis led to FDA...

Co-precipitation towards improved performance of amorphous solid dispersion based drug products

By Dr. Ashish Punia, Ph.D. Merck & Co., Rahway, NJ A considerable portion of small molecule pharmaceutical drugs suffer from poor aqueous solubility. Amorphous solid dispersion (ASD) is a...

Enhanced Properties of Solid Oral Dosages via API Co-Processing: Dry Coating of APIs and Synergistic Effects

By Prof. Rajesh N. Davé, Distinguished Professor, Chemical & Materials Engineering, New Jersey Institute of Technology, Newark, NJ 07102 Distinguished Professor of Chemical, Biological and Pharmaceutical Engineering, Center for...

Solving Punch Sticking Problems During Tablet Manufacturing Through Crystal Engineering of APIs

By Prof. Changquan Calvin Sun, Ph.D. Professor, University of Minnesota The development of a quality tablet product requires overcoming deficiencies in pharmaceutical properties of tablets to meet several performance...

Stabilization of Amorphous Drugs by Polymers: The Role of C*

By Prof. Ronald Siegel, Professor and Department Head, Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455 For many low solubility drugs, the crystalline form is unfavorable due to...

Enabling Drug Product Performance via Amorphous Solid Dispersion Technique

By Samuel kyeremateng, Ph.D. AbbVie, North Chicago, IL Small molecule solid dosage drug product with the drug in the crystalline state is typically preferred due its more desirable properties...

Absolute configuration determination of small molecules with X-ray and electron diffraction

By Dr. Bo Wang, Ph.D. Biogen, Cambridge, MA Absolute configuration determination of an active pharmaceutic ingredient (API) is a crucial task in drug development. Tremendous scientific and technical progress...

Virtual Polymorph Screening and Targeted Crystallization Powered by in silico Solid-state Modeling

By Dedong Wu, Ph.D. Advanced Drug Delivery, PharmSci, R&D, AstraZeneca, Boston US dedong.wu@astrazeneca.com It is challenging and laborious to identify a crystallization process to access an optimal drug substance...

Enabling Green Synthetic Innovations at Merck: Three Examples of Leveraging the Unique Physical Properties of the Solid Phase to Accelerate and Implement Greener Chemical Processes.

By Scott Shultz, Ph.D. Department of Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, USA The role of the crystalline solid phase is often an enabling feature...

Development of a scalable atroposelective process to MRTX1719-an inhibitor of the PRMT5*MTA complex

By Cheng Yi Chen, Ph.D. Chemical Processing R&D, Mirati Therapeutics, San Diego, CA 92130, USA chenc@mirati.com A new approach to stereopure atropisomeric molecules is enabled by a continuous flow-crystallization...

RSS
Follow by Email
LinkedIn
Share